{'52WeekChange': 1.6265306,
 'SandP52WeekChange': None,
 'address1': '320 West 37th Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24.45,
 'askSize': 1000,
 'averageDailyVolume10Day': 157125,
 'averageVolume': 431117,
 'averageVolume10days': 157125,
 'beta': None,
 'beta3Year': None,
 'bid': 24.39,
 'bidSize': 1100,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 25.74,
 'dayLow': 24.235,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -29.101,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1855415296,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 25.514572,
 'fiftyTwoWeekHigh': 29.96,
 'fiftyTwoWeekLow': 8.34,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25477334,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 42,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.73181,
 'heldPercentInstitutions': 0.21096,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1585612800,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/immunovant.com',
 'longBusinessSummary': 'Immunovant, Inc., a clinical-stage biopharmaceutical '
                        'company, develops monoclonal antibodies for the '
                        'treatment of autoimmune diseases. It develops '
                        'IMVT-1401, a novel fully human monoclonal antibody '
                        'that selectively binds to and inhibits the neonatal '
                        'fragment crystallizable receptor, which is in Phase '
                        'IIa clinical trials for the treatment of myasthenia '
                        'gravis and thyroid eye disease, as well as has '
                        'completed initiation of Phase II clinical trials for '
                        'the treatment of warm autoimmune hemolytic anemia. '
                        'The company is headquartered in New York, New York. '
                        'Immunovant, Inc. is a subsidiary of Roivant Sciences '
                        'Ltd.',
 'longName': 'Immunovant, Inc.',
 'market': 'us_market',
 'marketCap': 1997023488,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_592774643',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -66388000,
 'nextFiscalYearEnd': 1648684800,
 'open': 25.74,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '917 580 3099',
 'previousClose': 25.74,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 25.74,
 'regularMarketDayLow': 24.235,
 'regularMarketOpen': 25.74,
 'regularMarketPreviousClose': 25.74,
 'regularMarketPrice': 25.74,
 'regularMarketVolume': 164103,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 81811696,
 'sharesPercentSharesOut': 0.0164,
 'sharesShort': 1339652,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1027935,
 'shortName': 'Immunovant, Inc.',
 'shortPercentOfFloat': 0.0387,
 'shortRatio': 1.9,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'IMVT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 19.069965,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'd116cec5-659e-37a8-8d49-e874f7dd0477',
 'volume': 164103,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.immunovant.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10018'}